Alembic Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE901L01018
  • NSEID: APLLTD
  • BSEID: 533573
INR
1,041.40
-7.35 (-0.7%)
BSENSE

Nov 20

BSE+NSE Vol: 2.04 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Alembic Pharma
Acutaas Chemical
Rubicon Research
Alivus Life
Piramal Pharma
Granules India
Neuland Labs.
Shilpa Medicare
OneSource Speci.
ERIS Lifescience
Pfizer
Why is Alembic Pharmaceuticals Ltd. ?
1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.99 times
2
With a growth in Net Profit of 83.92%, the company declared Very Positive results in Sep 26
  • ROCE(HY) Highest at 14.93%
  • OPERATING PROFIT TO INTEREST(Q) Highest at 14.72 times
  • NET SALES(Q) Highest at Rs 2,603.48 cr
3
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 04-Nov-26 and has generated 14.79% returns since then
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band, KST and OBV
4
With ROCE of 14.5, it has a Attractive valuation with a 3 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 15.87%, its profits have risen by 42.4% ; the PEG ratio of the company is 0.5
5
Majority shareholders : Promoters
6
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
  • It is ranked 5 across all Small Cap and 15 across the entire market
stock-recommendationReal-Time Research Report
Verdict Report
How much should you buy?
  1. Overall Portfolio exposure to Alembic Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Alembic Pharma for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Alembic Pharma
15.87%
0.50
31.87%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
10.21%
EBIT Growth (5y)
1.93%
EBIT to Interest (avg)
10.24
Debt to EBITDA (avg)
1.06
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
1.05
Tax Ratio
10.66%
Dividend Payout Ratio
37.06%
Pledged Shares
0
Institutional Holding
19.98%
ROCE (avg)
11.12%
ROE (avg)
11.48%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
23
Industry P/E
40
Price to Book Value
3.46
EV to EBIT
20.80
EV to EBITDA
15.41
EV to Capital Employed
3.02
EV to Sales
2.57
PEG Ratio
0.54
Dividend Yield
1.15%
ROCE (Latest)
14.51%
ROE (Latest)
15.19%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

29What is working for the Company
ROCE(HY)

Highest at 14.93%

OPERATING PROFIT TO INTEREST(Q)

Highest at 14.72 times

NET SALES(Q)

Highest at Rs 2,603.48 cr

PBDIT(Q)

Highest at Rs 563.27 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 21.64%

PBT LESS OI(Q)

Highest at Rs 422.84 cr.

PAT(Q)

Highest at Rs 335.17 cr.

EPS(Q)

Highest at Rs 17.05

-9What is not working for the Company
DEBTORS TURNOVER RATIO(HY)

Lowest at 4.47 times

INTEREST(Q)

Highest at Rs 38.26 cr

Loading Valuation Snapshot...
Here's what is working for Alembic Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 422.84 cr has Grown at 95.03%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 335.17 cr has Grown at 81.5%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Operating Profit to Interest - Quarterly
Highest at 14.72 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Net Sales - Quarterly
Highest at Rs 2,603.48 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 2,603.48 cr has Grown at 36.30%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 563.27 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 21.64%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 422.84 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 335.17 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 17.05
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Alembic Pharma
Interest - Quarterly
At Rs 38.26 cr has Grown at 38.57%
Quarter on Quarter (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Interest - Quarterly
Highest at Rs 38.26 cr
in the last five quarters and Increased by 38.57 % (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Debtors Turnover Ratio- Half Yearly
Lowest at 4.47 times
in the last five half yearly periods
MOJO Watch
Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio